Xilio doses first patient in Phase 1/2 trial of PD-1/IL-2 bispecific XTX501
Xilio reported third-quarter 2026 results alongside pipeline updates, including dosing in the XTX501 lung cancer trial and two preclinical programs advancing toward 2027 IND filings.
SEC filing